Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 1;19(9):501.
doi: 10.3390/md19090501.

The Role of Chitosan Oligosaccharide in Metabolic Syndrome: A Review of Possible Mechanisms

Wenjing Tao  1 , Geng Wang  2 , Jintao Wei  1
Affiliations
Review

The Role of Chitosan Oligosaccharide in Metabolic Syndrome: A Review of Possible Mechanisms

Wenjing Tao et al. Mar Drugs. .

Abstract

Metabolic syndrome, a cluster of metabolic disorders including central obesity, insulin resistance, hyperglycemia, dyslipidemia, and hypertension, has become a major public health problem worldwide. It is of great significance to develop natural products to prevent and treat metabolic syndrome. Chitosan oligosaccharide (COS) is an oligomer of chitosan prepared by the deacetylation of chitin, which is the second most abundant polymer in nature. In recent years, COS has received widespread attention due to its various biological activities. The present review will summarize the evidence from both in vitro and in vivo studies of the beneficial effects of COS on obesity, dyslipidemia, diabetes mellitus, hyperglycemia, and hypertension, and focus attention on possible mechanisms of the prevention and treatment of metabolic syndrome by COS.

Keywords: chitosan oligosaccharide; diabetes; hypertension; metabolic syndrome; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms involved in the regulation of obesity and dyslipidemia by COS.
Figure 2
Figure 2
Mechanisms involved in the regulation of diabetes and hyperglycemia by COS.
See this image and copyright information in PMC

References

    1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005;365:1415–1428. doi: 10.1016/S0140-6736(05)66378-7. - DOI - PubMed
    1. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018;20:12. doi: 10.1007/s11906-018-0812-z. - DOI - PMC - PubMed
    1. Huang P.L. A comprehensive definition for metabolic syndrome. Dis. Models Mech. 2009;2:231–237. doi: 10.1242/dmm.001180. - DOI - PMC - PubMed
    1. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C., Jr. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. doi: 10.1161/circulationaha.109.192644. - DOI - PubMed
    1. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., Rinfret S., Schiffrin E.L., Eisenberg M.J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010;56:1113–1132. doi: 10.1016/j.jacc.2010.05.034. - DOI - PubMed

MeSH terms